Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03508609|
Recruitment Status : Completed
First Posted : April 26, 2018
Results First Posted : January 8, 2021
Last Update Posted : January 8, 2021
|Condition or disease||Intervention/treatment||Phase|
|Coronary Microvascular Dysfunction||Biological: CLBS16||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-Label Exploratory Clinical Study to Evaluate the Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction (CMD) and Without Obstructive Coronary Artery Disease|
|Actual Study Start Date :||April 19, 2018|
|Actual Primary Completion Date :||December 10, 2019|
|Actual Study Completion Date :||May 5, 2020|
Experimental: Autologous CD34 cells
Open label active treatment arm. Subjects receive autologous CD34 cells.
GCSF-mobilized autologous CD34 cells
- Change From Baseline in Coronary Flow Reserve [ Time Frame: Day 180 ]Coronary Flow Reserve (CFR) is a measure of coronary microvascular function.
- Change From Baseline in Microvascular Function as Assessed by Intracoronary Administration of Acetylcholine [ Time Frame: Day 180 ]
- Change From Baseline in Peripheral Arterial Tonometry [ Time Frame: Day 180 ]
- Change in Angina Frequency From Baseline [ Time Frame: 6 months ]
- Canadian Cardiovascular Society Angina Class [ Time Frame: 6 months ]
Canadian Cardiovascular Society angina class grading scale is assessed according to the following scores:
Grade 1: Ordinary physical activity does not cause angina, such as walking and climbing stairs. Angina with strenuous or rapid or prolonged exertion at work or recreation Grade 2: Slight limitation of ordinary activity. Walking or climbing stairs rapidly, walking uphill, walking or stair climbing after meals, or in cold, or in wind, or under emotional stress, or only during the few hours after awakening. Walking more than two blocks on the level and climbing more than one flight of ordinary stairs at a normal pace and in normal conditions Grade 3: Marked limitation of ordinary physical activity. Walking one or two blocks on the level and climbing one flight of stairs in normal conditions and at normal pace Grade 4: Inability to carry on any physical activity without discomfort, anginal syndrome may be present at rest A higher grade is a worse outcome.
- Change From Baseline in Seattle Angina Questionnaire [ Time Frame: 6 months ]The SAQ quantifies patients' physical limitations caused by angina, the frequency of and recent changes in their symptoms, their satisfaction with treatment, and the degree to which they perceive their disease to affect their quality of life. Each scale is transformed to a score of 0 to 100, where higher scores indicate better function (eg, less physical limitation, less angina, and better quality of life).
- Change From Baseline in SF-36 Scores [ Time Frame: 6 months ]The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03508609
|United States, California|
|Cedars-Sinai Medical Center|
|Los Angeles, California, United States, 90048|
|United States, Minnesota|
|Mayo Clinic in Rochester|
|Rochester, Minnesota, United States, 55905|
|Study Director:||Douglas W. Losordo, MD||Chief Medical Officer|